000 | 01943 a2200481 4500 | ||
---|---|---|---|
005 | 20250515215751.0 | ||
264 | 0 | _c20100709 | |
008 | 201007s 0 0 eng d | ||
022 | _a1471-2474 | ||
024 | 7 |
_a10.1186/1471-2474-11-61 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWestra, Johanna | |
245 | 0 | 0 |
_aExpression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. _h[electronic resource] |
260 |
_bBMC musculoskeletal disorders _cMar 2010 |
||
300 |
_a61 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aArthritis _xdrug therapy |
650 | 0 | 4 |
_aBiomarkers _xmetabolism |
650 | 0 | 4 |
_aCalcium-Calmodulin-Dependent Protein Kinase Type 2 _xantagonists & inhibitors |
650 | 0 | 4 | _aCell Line |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xdrug effects |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoxia-Inducible Factor 1, alpha Subunit _xgenetics |
650 | 0 | 4 |
_aInterleukin-8 _xdrug effects |
650 | 0 | 4 |
_aMacrophages _xdrug effects |
650 | 0 | 4 |
_aMatrix Metalloproteinase 9 _xdrug effects |
650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xdrug effects |
650 | 0 | 4 |
_aRNA, Messenger _xdrug effects |
650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
650 | 0 | 4 |
_aSynovial Membrane _xcytology |
650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xgenetics |
700 | 1 | _aBrouwer, Elisabeth | |
700 | 1 | _avan Roosmalen, Ingrid A M | |
700 | 1 | _aDoornbos-van der Meer, Berber | |
700 | 1 | _avan Leeuwen, Miek A | |
700 | 1 | _aPosthumus, Marcel D | |
700 | 1 | _aKallenberg, Cees G M | |
773 | 0 |
_tBMC musculoskeletal disorders _gvol. 11 _gp. 61 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2474-11-61 _zAvailable from publisher's website |
999 |
_c19714263 _d19714263 |